We have located links that may give you full text access.
Risk Severity Model for Pediatric Autosomal Dominant Polycystic Kidney Disease Using 3D Ultrasound Volumetry.
Clinical Journal of the American Society of Nephrology : CJASN 2023 Februrary 18
BACKGROUND: Height-adjusted total kidney volume (htTKV) measured by imaging defined as Mayo Imaging Class (MIC) is a validated prognostic measure for autosomal dominant polycystic kidney disease (ADPKD) in adults to predict and stratify disease progression. However, no stratification tool is currently available in pediatric ADPKD. Since magnetic resonance imaging and computed tomography in children are difficult, we propose a novel 3D ultrasound based pediatric Leuven Imaging Classification (LIC) to complement the MIC.
METHODS: A prospective study cohort of seventy-four genotyped ADPKD patients (37 female) is followed longitudinally with ultrasound including 3D ultrasound and they underwent in total 247 3D ultrasound assessments, with patients' median age (interquartile range) at diagnosis of 3 (0-9) years and at first 3D ultrasound evaluation of 10 (5-14) years with htTKV of 161 (117-208) mL/m. First, data matching was done to the published MIC classification, followed by subsequent optimization of parameters and model type.
RESULTS: PKD1 was confirmed in 70 patients (95%), PKD2 in three (4%), and GANAB only once (1%). Over these 247 evaluations, the median height was 143 (122-166) cm and total kidney volume was 236 (144-344) mL, leading to an htTKV of 161 (117-208) mL/m. Applying the adult Mayo classification below the age of 15 years strongly underestimated ADPKD severity in children, even with correction for height. We therefore optimized the model with our pediatric data and eventually validated it with data of young patients from Mayo Clinic and the CRISP Consortium used to establish the MIC.
CONCLUSIONS: We proposed a 5-level "LIC ADPKD Pediatric Model" as a novel classification tool based on patients' age and 3D ultrasound-htTKV for reliable discrimination of childhood ADPKD severity.
METHODS: A prospective study cohort of seventy-four genotyped ADPKD patients (37 female) is followed longitudinally with ultrasound including 3D ultrasound and they underwent in total 247 3D ultrasound assessments, with patients' median age (interquartile range) at diagnosis of 3 (0-9) years and at first 3D ultrasound evaluation of 10 (5-14) years with htTKV of 161 (117-208) mL/m. First, data matching was done to the published MIC classification, followed by subsequent optimization of parameters and model type.
RESULTS: PKD1 was confirmed in 70 patients (95%), PKD2 in three (4%), and GANAB only once (1%). Over these 247 evaluations, the median height was 143 (122-166) cm and total kidney volume was 236 (144-344) mL, leading to an htTKV of 161 (117-208) mL/m. Applying the adult Mayo classification below the age of 15 years strongly underestimated ADPKD severity in children, even with correction for height. We therefore optimized the model with our pediatric data and eventually validated it with data of young patients from Mayo Clinic and the CRISP Consortium used to establish the MIC.
CONCLUSIONS: We proposed a 5-level "LIC ADPKD Pediatric Model" as a novel classification tool based on patients' age and 3D ultrasound-htTKV for reliable discrimination of childhood ADPKD severity.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app